The approval is supported by bioequivalence data assessing the once-daily extended-release formulation to twice-daily immediate-release ruxolitinib in healthy participants.
FDA cleared once-daily ruxolitinib XR for MF, HU-refractory/intolerant PV, and steroid-refractory acute/chronic GVHD after ...
VDPHL01 is in multiple Phase 3 clinical trials as the potential first and only extended-release oral minoxidil for women and men with pattern hair loss – one of the largest aesthetics conditions ...
A batch of Xanax XR has been recalled nationwide after the manufacturer found the drug may not release properly in the body. The FDA classified the issue as moderate risk.
In a randomized trial, both 100-mg and 300-mg monthly maintenance doses of extended-release buprenorphine improved opioid abstinence in patients with high-risk opioid use, with no new safety signals.
A specific batch of extended-release Xanax failed a key quality test.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results